SCHEMBL4026128

SCHEMBL4026128

Cc1cccc(C2[C@@H](C(=O)c3ccccc3)CN(CC(=O)NCCN3CCOCC3)C[C@@H]2C(=O)c2ccccc2)c1C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 2/20 0.45
GAA P10253 2/20 0.45
MAPT P10636 1/20 0.45
KDM4E B2RXH2 3/20 0.45
TSHR P16473 3/20 0.44
RXFP1 Q9HBX9 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 3/20 0.43
CYP2C19 P33261 3/20 0.43
CYP3A4 P08684 2/20 0.43
HPGD P15428 2/20 0.43
CD274 Q9NZQ7 1/20 0.43
EPHX2 P34913 1/20 0.43
CYP2C9 P11712 2/20 0.42
CYP1A2 P05177 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4026132 1.00 MEN1 (0.45) MEN1KMT2APOLBGAAMAPT
SCHEMBL4776822 0.89 ALDH1A1 (0.46) MEN1KMT2APOLBMAPTKDM4E
SCHEMBL4777781 0.89 ALDH1A1 (0.46) MEN1KMT2APOLBMAPTKDM4E
SCHEMBL4780063 0.89 ALDH1A1 (0.46) MEN1KMT2APOLBMAPTKDM4E
SCHEMBL4024726 0.89 MAPT (0.47) MEN1KMT2APOLBGAAMAPT
SCHEMBL4024732 0.89 MAPT (0.47) MEN1KMT2APOLBGAAMAPT
SCHEMBL4028786 0.86 MEN1 (0.40) MEN1KMT2APOLBGAAMAPT
SCHEMBL4894830 0.86 POLB (0.44) MEN1KMT2APOLBGAAMAPT
SCHEMBL4795657 0.86 POLB (0.44) MEN1KMT2APOLBGAAMAPT
SCHEMBL4028782 0.86 MEN1 (0.40) MEN1KMT2APOLBGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 MEN1 77/4885KMT2A 2820/4885POLB 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.